Accuray Grants Equity Awards to New CEO Stephen La Neve to Drive Strategic Growth

Accuray Welcomes New CEO with Strategic Equity Inducement Awards

Accuray Incorporated announces the approval of substantial equity inducement awards to its newly appointed Chief Executive Officer, Stephen La Neve, as part of a strategic initiative to strengthen leadership and enhance the company’s future. On October 31, 2025, the Board of Directors grants Mr. La Neve 1.5 million restricted stock units (RSUs) and an equal number of performance-based restricted stock units (PSUs) as an incentive for his leadership role. This move is in compliance with NASDAQ Listing Rules and aims to align Mr. La Neve’s interests with those of the company, fostering a culture of performance and accountability right from his start date.

The structure of the equity awards reflects Accuray’s commitment to long-term growth and shareholder value. The RSUs will vest annually at a rate of 25% on each anniversary of the grant date, contingent upon Mr. La Neve’s continued service with the company. Meanwhile, the PSUs are designed to incentivize performance linked to stock price achievements over a six-year period, culminating on September 30, 2031. The awards are strategically divided into three tranches, each contingent upon reaching specific stock price milestones, with increasing targets that encourage sustained performance improvement. This approach not only motivates Mr. La Neve but also aligns his success with the company's overall performance.

Accuray’s emphasis on leveraging advancements in radiation therapy to improve patient outcomes is central to its mission. Under Mr. La Neve's leadership, the company is poised to navigate the evolving landscape of oncology and radiation treatment, focusing on innovation and the delivery of high-quality care. By tying executive compensation to performance metrics, Accuray reinforces its dedication to achieving measurable results, enhancing its competitive edge in the medical technology field. This strategic decision signals the company’s commitment to fostering a results-oriented culture that prioritizes both innovation in cancer treatment and the well-being of patients.

In addition to the equity awards, Accuray remains focused on its core mission to advance radiation therapy technologies that enhance patient care and quality of life. The company’s efforts in research and development are crucial as they aim to meet the increasing demand for effective cancer treatments. Accuray’s leadership transition, marked by the appointment of Stephen La Neve, is expected to drive these initiatives forward, ensuring that the company remains at the forefront of the medical technology industry.

Overall, the approval of these significant inducement awards not only reflects Accuray's strategic direction but also positions it to effectively respond to the challenges and opportunities within the rapidly evolving healthcare landscape.